OBJECTIVE: De novo donor-specific anti-human leukocyte antigen antibodies develop in a high proportion of lung transplant recipients early after lung transplantation. We recently showed that de novo donor-specific antibodies (DSA) occurrence is associated with significantly increased mortality. Here, we studied the efficacy of a preemptive treatment protocol. METHODS: A retrospective observational study was conducted on all lung transplantations at Hanover Medical School between January 2009 and May 2013. RESULTS: Among the 500 transplant recipients, early DSA developed in 86 (17%). Of these, 56 patients (65%; Group A) received therapeutic plasma exchange, and 30 patients (35%; Group B) did not. Among Group A patients, 51 also received rituximab. Between groups, there was no statistically significant difference in mortality, incidence of pulsed steroid therapies, rejections diagnosed by biopsy specimen, incidence of bronchitis obliterans syndrome (BOS), or infections requiring hospitalization at 1 year and 3 years. Also, there were no statistically significant differences after matching 21 Group A with 21 Group B patients through propensity score analysis. Significantly more Group A patients (65%) than Group B patients (34%) cleared DSA at hospital discharge (p = 0.01). At the last control after transplantation (median, 14 months; interquartile range, 5-24 months), 11 Group A (22%) and 9 Group B patients (33%) still showed DSA (p = 0.28). CONCLUSIONS: Preemptive treatment with therapeutic plasma exchange and rituximab led to improved elimination of DSA early after lung transplantation (p = 0.01). However, spontaneous elimination in untreated Group B patients also occurred frequently. This treatment protocol was not associated with significantly improved outcome.
RCT Entities:
OBJECTIVE: De novo donor-specific anti-human leukocyte antigen antibodies develop in a high proportion of lung transplant recipients early after lung transplantation. We recently showed that de novo donor-specific antibodies (DSA) occurrence is associated with significantly increased mortality. Here, we studied the efficacy of a preemptive treatment protocol. METHODS: A retrospective observational study was conducted on all lung transplantations at Hanover Medical School between January 2009 and May 2013. RESULTS: Among the 500 transplant recipients, early DSA developed in 86 (17%). Of these, 56 patients (65%; Group A) received therapeutic plasma exchange, and 30 patients (35%; Group B) did not. Among Group A patients, 51 also received rituximab. Between groups, there was no statistically significant difference in mortality, incidence of pulsed steroid therapies, rejections diagnosed by biopsy specimen, incidence of bronchitis obliterans syndrome (BOS), or infections requiring hospitalization at 1 year and 3 years. Also, there were no statistically significant differences after matching 21 Group A with 21 Group B patients through propensity score analysis. Significantly more Group A patients (65%) than Group B patients (34%) cleared DSA at hospital discharge (p = 0.01). At the last control after transplantation (median, 14 months; interquartile range, 5-24 months), 11 Group A (22%) and 9 Group B patients (33%) still showed DSA (p = 0.28). CONCLUSIONS: Preemptive treatment with therapeutic plasma exchange and rituximab led to improved elimination of DSA early after lung transplantation (p = 0.01). However, spontaneous elimination in untreated Group B patients also occurred frequently. This treatment protocol was not associated with significantly improved outcome.
Authors: Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: Oluwatoyosi A Onwuemene; Steven C Grambow; Chetan B Patel; Robert J Mentz; Carmelo A Milano; Joseph G Rogers; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel Journal: J Clin Apher Date: 2018-03-10 Impact factor: 2.821
Authors: Ramsey R Hachem; Malek Kamoun; Marie M Budev; Medhat Askar; Vivek N Ahya; James C Lee; Deborah J Levine; Marilyn S Pollack; Gundeep S Dhillon; David Weill; Kenneth B Schechtman; Lorriana E Leard; Jeffrey A Golden; LeeAnn Baxter-Lowe; Thalachallour Mohanakumar; Dolly B Tyan; Roger D Yusen Journal: Am J Transplant Date: 2018-05-15 Impact factor: 8.086
Authors: Alberto Benazzo; Nina Worel; Stefan Schwarz; Ulrike Just; Anna Nechay; Christoph Lambers; Georg Böhmig; Gottfried Fischer; Daniela Koren; Gabriela Muraközy; Robert Knobler; Walter Klepetko; Konrad Hoetzenecker; Peter Jaksch Journal: Transfus Med Hemother Date: 2020-05-05 Impact factor: 3.747
Authors: Fabio Ius; Wiebke Sommer; Daniela Kieneke; Igor Tudorache; Christian Kühn; Murat Avsar; Thierry Siemeni; Jawad Salman; Carolin Erdfelder; Murielle Verboom; Jan Kielstein; Andreas Tecklenburg; Mark Greer; Michael Hallensleben; Rainer Blasczyk; Nicolaus Schwerk; Jens Gottlieb; Tobias Welte; Axel Haverich; Gregor Warnecke Journal: Transplantation Date: 2016-12 Impact factor: 4.939
Authors: Carsten Hafer; Paulina Golla; Marion Gericke; Gabriele Eden; Gernot Beutel; Julius J Schmidt; Bernhard M W Schmidt; Stef De Reys; Jan T Kielstein Journal: Int Urol Nephrol Date: 2015-11-03 Impact factor: 2.370